" class="no-js "lang="en-US"> Fundraising Archives - Page 26 of 41 - Medtech Alert
Monday, October 20, 2025

Sort by:

Date

Top Post

Novalis Biotech Invests in Ultra Sensitive Genomics Technology by Rarity Bioscience

Rarity Bioscience announces a new strategic investment from Belgium-based Novalis Biotech. The investment is facilitated […]

Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection

Freenome, a privately held biotech company, today announced a Series D funding of $300 million. […]

Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19

Sosei Group Corporation (“the Company”; TSE: 4565) today announced it has received grant funding from […]

HypnoVR Raises €4.5 Million to Accelerate the Roll Out of its Digital Therapy Treating Pain and Anxiety

HypnoVR, a market leader in the field of digital therapies to manage pain and stress, […]

Vinehealth Raises $5.5m to Improve the Quality of Life and Survival of Cancer Patients

Today, Vinehealth announces it has raised $5.5m in seed funding. The round was led by […]

Holmusk Announces Closing of Strategic Investment from Healthcare and Life Science Industry Leaders

Holmusk, a leading global data science and digital health company building the world’s largest Real-World […]

PDC*line Pharma Raises €17.5 Million ($20.3M) in Series B2 Financing Round

PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable […]

Sixfold Bioscience Completes $10.5M USD (£7.8M GBP) Seed Financing

Sixfold Bioscience (Sixfold), a company harnessing computation and advanced chemistry to design RNA therapeutic delivery […]

EverImmune Raises €5M to Enter Clinical Phase in Microbiota Immuno-oncology

EverImmune, a biotechnology company specialized in the development of live biotherapeutic products in the field […]

Northwest Biotherapeutics Announces $15 Million Financing

Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more